Actelion reports first Uptravi sales, raises guidance

Actelion Ltd. (SIX:ATLN) reported 1Q16 earnings, including the first sales of pulmonary arterial hypertension drug Uptravi selexipag, and raised its

Read the full 204 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE